Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
SUBSCRIBE
Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
Global Market Bulletin
No Result
View All Result
Home Stock Market News

Gilat (GILT) Wins $4M U.S. Defense Contract for Transportable Satellite Hubs

by Global Market Bulletin
November 6, 2024
in Stock Market News
0
Gilat (GILT) Wins $4M U.S. Defense Contract for Transportable Satellite Hubs

Gilat (GILT) Wins $4M U.S. Defense Contract for Transportable Satellite Hubs

15
SHARES
33
VIEWS
Share on FacebookShare on Twitter

Gilat Satellite Networks Ltd. (GILT), a global leader in satellite networking technology, has won a contract exceeding $4 million from the U.S. Department of Defense. The contract involves supplying Gilat’s U.S. subsidiary, DataPath, with DKET 3421 terminals—advanced transportable satcom hubs designed for rapid deployment in critical military missions. The terminals are expected to be delivered in the first half of 2025.

You might also like

Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

Gilat (GILT) Wins $4M U.S. Defense Contract for Transportable Satellite Hubs

CHECK THIS OUT: Treace Medical (TMCI) Reports $44.5M Q2 Revenue, 6% Growth in Q2 2024

Key Features of Gilat’s DKET 3421 Terminals

The DKET 3421 terminal offers crucial capabilities for high-stakes military communications. Each unit supports multi-carrier operations and a scalable modem architecture of up to 32 modems, ensuring flexibility and robust performance in field operations.

Weighing under 5,000 lbs., the DKET 3421 terminal is designed for quick transport and setup, deploying in under three hours. This single-skid hub provides adaptable satellite connectivity to meet a wide range of mission requirements.

A Trusted Partner for Critical Defense Solutions

Nicole Robinson, President of DataPath, emphasized that the repeat order underscores the U.S. military’s trust in Gilat’s advanced technology.

“This order highlights our commitment to delivering dependable, high-performance solutions for mission-critical defense applications,” said Robinson.

“We are proud to support the evolving needs of our defense customers.”

About Gilat Satellite Networks

Gilat Satellite Networks Ltd. has over 35 years of expertise in providing cutting-edge satellite-based communications solutions. Known for its secure, end-to-end solutions for broadband, ground, and new space communications, Gilat serves a broad range of industries, including commercial, government, and defense.

The company’s mission is to connect the world, bringing reliable communication to underserved regions and supporting essential operations around the globe.

With this new contract, Gilat strengthens its position as a trusted technology provider to the U.S. Department of Defense, enhancing operational success across global missions.

READ ALSO: Spirit Airlines in Q2 2024: $1.28B Revenue, Plus New Travel Options and Canadian Solar (CSIQ) Reports $1.6B Revenue with Solar and Storage.

Tags: Gilat Satellite Networks Ltd. (GILT)
Share6Tweet4

Global Market Bulletin

Global Market Bulletin is a leading provider of stock market updates, economic news, and personalized investing guides. Our team brings you the latest global financial information to help you make smart investment decisions. About the Editorial Team Our editorial team consists of financial experts and seasoned market analysts who bring decades of experience to our coverage. With a commitment to unbiased reporting, our team ensures that every article is backed by thorough research and delivers accurate financial insights.

Recommended For You

Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

by Global Market Bulletin
July 18, 2026
0
Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

by Global Market Bulletin
July 18, 2026
0
Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

by Global Market Bulletin
July 18, 2026
0
Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

What Makes SharpLink (SBET) a High-Risk Stock Investors Cannot Ignore?

by Global Market Bulletin
July 18, 2026
0
What Makes SharpLink (SBET) a High-Risk Stock Investors Cannot Ignore?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Is Omeros (OMER) a Smart Biotech Investment Before Its Next Major Catalyst?

by Global Market Bulletin
July 18, 2026
0
Is Omeros (OMER) a Smart Biotech Investment Before Its Next Major Catalyst?

We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10...

Read moreDetails

Browse by Category

  • CEO Interviews
  • Economy
  • Investing
  • Stock Market News
  • Uncategorized

QUICK LINKS

  • Stock Market News
  • Investing
  • Economy
  • Contact Us
  • About Global Market Bulletin
  • Editorial Policy – Global Market Bulletin
  • Our Editorial Team

RECENT POSTS

  • Could ARS Pharmaceuticals (SPRY) Disrupt the Emergency Allergy Treatment Market?
  • Is Lexeo Therapeutics (LXEO) a Good Gene Therapy Stock for Long-Term Growth?
  • Is Sagimet Biosciences (SGMT) a Promising Biotech Stock to Buy Before Its Next Catalyst?

GET EMAIL MARKET UPDATES

Subscribe to our mailing list to receives daily updates direct to your inbox!
  • Privacy Policy
  • Terms and Conditions

© 2022 Global Market Bulletin. All Rights Reserved.

No Result
View All Result
  • Home
  • Stock Market News
  • Investing
  • Economy

© 2022 Global Market Bulletin. All Rights Reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?